Table II.

Comparison of genotypic distributions and allele frequencies of the two eNOS gene polymorphisms between the LCPD and healthy control groups.

				LCPD vs. healthy control
Polymorphism	Genotype/Allele	LCPD (n=80)	Healthy control (n=100)	OR	95% CI	P-value
eNOS 27 bp VNTR, n (%)	bb	58 (72.5)	86 (86.0)	1
	ab	22 (27.5)	14 (14.0)	2.33	1.10–4.92	0.024
	aa	0 (0)	0 (0)
	b	138 (86.2)	186 (93.0)	1
	a	22 (13.8)	14 (7.0)	2.12	1.05–4.29	0.034
eNOS G894T, n (%)	GG	50 (62.5)	81 (81.0)	1
	GT	28 (35.0)	17 (17.0)	2.67	1.33–5.36	0.005
	TT	2 (2.5)	2 (2.0)	1.62	0.22–11.87	0.632
	G	128 (80.0)	179 (89.5)	1
	T	32 (20.0)	21 (10.5)	2.13	1.18–3.87	0.011

eNOS, endothelial nitric oxide synthase; VNTR, variable number tandem repeat; LCPD, Legg-Calvé-Perthes disease.